Loading clinical trials...
Loading clinical trials...
Acalabrutinib received European Medicines Agency approval on November 2020 for for CLL adult patients, either as monotherapy or in combination with obinutuzumab, in previously untreated patients or as...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AstraZeneca
NCT06846671 · CLL, Chronic Lymphocytic Leukemia
NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
NCT06548152 · Chronic Lymphocytic Leukemia
NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
Research Site
Piteşti, Argeş
Research Site
Oradea, Bihor County
Research Site
Cluj-Napoca, Cluj
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions